Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
UH15-38 is an inhibitor of receptor-interacting serine/threonine kinase 3 (RIPK3; IC50 = 0.02 µM).1 It is selective for RIPK3 over a panel of 50 receptors and enzymes at 1 µM and a panel of 77 kinases at 0.5 µM but does inhibit RIPK1 (IC50 = 0.024 µM) and 13 other kinases by greater than 90% at 0.5 µM. UH15-38 inhibits LPS-induced necroptosis in RAW 264.7 macrophages and isolated mouse bone marrow-derived macrophages (BMDMs; IC50s = 17 and 22 nM, respectively) and TNF-α-induced necroptosis in recombinant human RIPK3-expressing HeLa cells, Fas-associated death domain protein knockout (FADD-/-) Jurkat cells, and U937 cells (IC50s = 722, 205, and 329 nM, respectively). In vivo, UH15-38 (30 mg/kg) increases survival, decreases lung injury and immune cell bronchoalveolar fluid (BALF) infiltration, and inhibits decreases in arterial oxygen saturation in a mouse model of severe influenza A infection.
WARNING This product is not for human or veterinary use.
1. Necroptosis blockade prevents lung injury in severe influenza. Nature 628(8009), 835-843 (2024).